KR20240093606A - 치환된 1H-피라졸로[4,3-c] 퀴놀린, 이의 제조 방법 및 용도 - Google Patents

치환된 1H-피라졸로[4,3-c] 퀴놀린, 이의 제조 방법 및 용도 Download PDF

Info

Publication number
KR20240093606A
KR20240093606A KR1020247016127A KR20247016127A KR20240093606A KR 20240093606 A KR20240093606 A KR 20240093606A KR 1020247016127 A KR1020247016127 A KR 1020247016127A KR 20247016127 A KR20247016127 A KR 20247016127A KR 20240093606 A KR20240093606 A KR 20240093606A
Authority
KR
South Korea
Prior art keywords
alkyl
pyrazolo
methoxy
quinolin
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247016127A
Other languages
English (en)
Korean (ko)
Inventor
루벤 아바그얀
올렉 미트킨
블라디슬라프 제노노비치 파르친스키
알렉세이 푸셰크니코프
알렉산더 바실리에비치 이바크트첸코
니콜라이 사브추크
Original Assignee
로몬드 테라퓨틱스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 로몬드 테라퓨틱스 인코포레이티드 filed Critical 로몬드 테라퓨틱스 인코포레이티드
Publication of KR20240093606A publication Critical patent/KR20240093606A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/54—Three nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020247016127A 2021-10-15 2022-10-03 치환된 1H-피라졸로[4,3-c] 퀴놀린, 이의 제조 방법 및 용도 Pending KR20240093606A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163256260P 2021-10-15 2021-10-15
US63/256,260 2021-10-15
PCT/US2022/045555 WO2023064133A1 (en) 2021-10-15 2022-10-03 SUBSTITUTED 1H-PYRAZOLO [4,3-c] QUINOLINES, METHODS OF PREPARATION, AND USE THEREOF

Publications (1)

Publication Number Publication Date
KR20240093606A true KR20240093606A (ko) 2024-06-24

Family

ID=85988576

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247016127A Pending KR20240093606A (ko) 2021-10-15 2022-10-03 치환된 1H-피라졸로[4,3-c] 퀴놀린, 이의 제조 방법 및 용도

Country Status (11)

Country Link
US (1) US20250011319A1 (https=)
EP (1) EP4416146A4 (https=)
JP (1) JP2024539633A (https=)
KR (1) KR20240093606A (https=)
CN (1) CN118076605A (https=)
AU (1) AU2022364646B2 (https=)
CA (1) CA3233233A1 (https=)
MX (1) MX2024004569A (https=)
TW (2) TWI863003B (https=)
WO (1) WO2023064133A1 (https=)
ZA (1) ZA202406375B (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118666857B (zh) * 2024-06-26 2025-02-25 江西农业大学 一种喹啉类化合物及其在农用杀菌剂中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012080729A2 (en) * 2010-12-14 2012-06-21 Electrophoretics Limited CASEIN KINASE 1δ (CK1δ) INHIBITORS
MA42456B1 (fr) * 2015-06-25 2021-06-30 Univ Health Network Inhibiteurs de hpk1 et leurs procédés d'utilisation
US12486264B2 (en) * 2019-03-26 2025-12-02 Janssen Pharmaceutica Nv Bicyclic HPK1 inhibitors
US20210269434A1 (en) * 2020-01-10 2021-09-02 Incyte Corporation Tricyclic compounds as inhibitors of kras
AU2021254794A1 (en) * 2020-04-16 2022-12-15 Incyte Corporation Fused tricyclic KRAS inhibitors

Also Published As

Publication number Publication date
AU2022364646B2 (en) 2025-10-09
EP4416146A1 (en) 2024-08-21
ZA202406375B (en) 2025-01-29
CA3233233A1 (en) 2023-04-20
AU2022364646A1 (en) 2024-03-28
CN118076605A (zh) 2024-05-24
JP2024539633A (ja) 2024-10-29
TW202317567A (zh) 2023-05-01
TWI863003B (zh) 2024-11-21
TW202442645A (zh) 2024-11-01
MX2024004569A (es) 2024-04-30
US20250011319A1 (en) 2025-01-09
WO2023064133A1 (en) 2023-04-20
EP4416146A4 (en) 2025-11-05

Similar Documents

Publication Publication Date Title
CA2821712C (en) Substituted n-(1h-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type iii receptor tyrosine kinase inhibitors
JP7446236B2 (ja) ホスファチジルイノシトールリン酸キナーゼ阻害剤としてのアリール－ビピリジンアミン誘導体
JP7335893B2 (ja) ホスファチジルイノシトールリン酸キナーゼ阻害剤としてのクロメノピリジン誘導体
JP7569688B2 (ja) ホスファチジルイノシトールリン酸キナーゼ阻害剤としてのアミノピリジン誘導体
JP2018150358A (ja) Ｔａｎｋ結合キナーゼインヒビター化合物
AU2010254806A1 (en) Preparation and uses of 1,2,4-triazolo [1,5a] pyridine derivatives
NO342978B1 (no) Pyrimidin-derivat som PI3K-inhibitor og bruk av dette
EP2945623A1 (en) Hedgehog pathway signaling inhibitors and therapeutic applications thereof
CA2950330A1 (en) Certain protein kinase inhibitors
KR20180052702A (ko) Perk 억제제로서의 1-페닐피롤리딘-2-온 유도체
JP2021527654A (ja) Ｍａｌｔ１阻害剤としてのピラゾール誘導体
US20160083376A1 (en) Certain protein kinase inhibitors
CN114340634A (zh) 作为激酶抑制剂的杂环化合物
JP2024535867A (ja) 治療薬としてｎ－アリールピリミジン－２－アミン誘導体を有する化合物
KR102563829B1 (ko) 거대고리 rip2 키나아제 억제제
TWI863003B (zh) 經取代的 1H-吡唑并[4,3-c]喹啉、製備方法及其用途
JP2024512753A (ja) 新規なジアルコキシナフト［２，３－ｃ］フラン－１（３Ｈ）－オン誘導体およびこれを含む呼吸器疾患またはＳＡＲＳ－ＣｏＶ－２感染症の予防または治療用の薬学的組成物
CN116981458A (zh) 具有四氢吲哚-1-甲酰胺作为bcl-2抑制剂的化合物
JP7710756B2 (ja) Ｃｔｌａ－４低分子分解剤及びその使用
WO2023220541A1 (en) Tetrahydropyrido[3,4-d]pyrimidines compounds as hpk1 inhibitors
EP4619407A1 (en) Pyridone and pyrimidinone inhibitors of hematopoietic progenitor kinase 1
HK1190709B (en) Substituted n-(1h-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type iii receptor tyrosine kinase inhibitors

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20240514

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application